Kowa   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Nagoya Japan (1894)

Organization Overview

First Clinical Trial
2005
NCT00309738
First Marketed Drug
2009
pitavastatin (livalo)
First NDA Approval
2009
pitavastatin (livalo)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

IMAGE TECHNOLOGIES INC. | KOWA CO | Kowa Company, Ltd. | Kowa Pharmaceuticals America, Inc. | Kowa Pharma Development Co. | KOWA PHARMS | Kowa Research Europe | Kowa Research Europe (KRE) | Kowa Research Institute, Inc.

Active Ingredients

Marketed Drugs (3)

celecoxib (celebrex) (2021)

pitavastatin (livalo) (2009 NDA)

tramadol (Ultram) (2021)

Drugs in Phase 4 Trials (13)

atorvastatin (lipitor) (4 trials)

darunavir (prezista) (2 trials)

diltiazem (cardizem) (1 trial)

glimepiride (amaryl) (1 trial)

glucagon-like peptide-1 (1 trial)

insulin human (humulin) (1 trial)

lopinavir (Kaletra) (1 trial)

pitavastatin (livalo) (24 trials)

pravastatin (pravachol) (3 trials)

ritonavir (Norvir) (3 trials)

rosuvastatin (crestor) (2 trials)

tofogliflozin hydrate (5 trials)

warfarin (coumadin) (2 trials)

Drugs in Phase 3 Trials (9)

Key: Kowa (8) Acquired (1)

fenofibrate (fenoglide) (3 trials)

k-103-ip (1 trial)

k-877 (17 trials)

k-924 (2 trials)

pemafibrate (4 trials)

peretinoin (1 trial)

pro-513 (1 trial)

simvastatin (zocor) (3 trials)

ursodiol (1 trial)

Drugs in Phase 2 Trials (10)

cilostazol (pletal) (1 trial)

indomethacin (indocin) (2 trials)

k-134 (1 trial)

k-161 (1 trial)

k-321 (1 trial)

k-604 (1 trial)

menthol (Salonpas) (1 trial)

metformin (glucophage) (1 trial)

sitagliptin (januvia) (1 trial)

sk-0403 (2 trials)

Drugs in Phase 1 Trials (10)

clarithromycin (biaxin) (1 trial)

clopidogrel (plavix) (1 trial)

cyclosporine (sandimmune) (1 trial)

digoxin (lanoxin) (1 trial)

efavirenz (sustiva) (1 trial)

fluconazole (diflucan) (1 trial)

k-312 (3 trials)

k-755 (1 trial)

moxifloxacin (avelox) (1 trial)

rifampin (1 trial)

Drugs in Other Trials (4)

ezetimibe (zetia) (1 trial)

mci-196 (1 trial)

xanthophyll (1 trial)

zeaxanthin (1 trial)

Indications

Approved Indications


 

Dyslipidemias

Hyperlipidemias

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Pain (Phase 3)

Ankle Injuries (Phase 3)

Atherosclerosis (Phase 2)

Cardiovascular Diseases (Phase 4)

Corneal Dystrophies, Hereditary (Phase 2)

Coronary Artery Disease (Phase 3)

Coronary Disease (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Retinopathy (Phase 3)

Dry Eye Syndromes (Phase 2)

Dyslipidemias (Phase 4)

Eye Diseases (Phase 2)

Fatty Liver (Phase 4)

Fuchs' Endothelial Dystrophy (Phase 2)

Heart Diseases (Phase 3)

Hypercholesterolemia (Phase 4)

Hyperlipidemias (Phase 4)

Hyperlipoproteinemias (Phase 4)

Hypertriglyceridemia (Phase 3)

Intermittent Claudication (Phase 2)

Iridocorneal Endothelial Syndrome (Phase 2)

Keratoconjunctivitis Sicca (Phase 2)

Liver Diseases (Phase 4)

Liver Neoplasms (Phase 3)

Macular Edema (Phase 3)

Metabolic Syndrome (Phase 1)

Myalgia (Phase 2)

Myocardial Ischemia (Phase 3)

Neoplasms (Phase 3)

Non-alcoholic Fatty Liver Disease (Phase 4)

Recurrence (Phase 3)

Renal Insufficiency (Phase 4)

Retinal Diseases (Phase 3)

Sprains and Strains (Phase 3)

Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 68
  • # of Trial APIs: 46